Epi Data Slicer
Epi Data Slicer
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six new agents have been approved by the FDA (four of them since the start of 2021),…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six new agents have been approved by the FDA (four of them since the start of 2021),…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the key treatment goals are to protect the skin barrier, reduce inflammation, and alleviate itch…
Epidemiology Data Slicer – Dermatitis
Clarivate Epidemiology’s coverage of dermatitis comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis for each country,…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key dermatitis patient populations covering 171 countries and more than 99%…
Clarivate Epidemiology’s coverage of dermatitis comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis for each country,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AD patient populations covering 171 countries and more than 99% of…
MARKET OVERVIEW Chronic hand eczema (CHE) is a painful and debilitating form of eczema localized to the hands that can seriously impact a patient’s quality of life. No prescription therapies are…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
The approval of Dupixent has transformed the management of topical-refractory moderate to severe atopic dermatitis (AD), and the active, diverse AD pipeline is filled with compelling emerging…